Skip to main content

CORRECTION article

Front. Oncol., 13 December 2022
Sec. Cancer Molecular Targets and Therapeutics
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1113289

Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

This article is a correction to:

  1. Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

    1. Read original article
Sha-Sha Wang&#x;Sha-Sha Wang1†Fang Wang&#x;Fang Wang2†Zhen ZengZhen Zeng1Fang GaoFang Gao1Huan-Huan LiuHuan-Huan Liu3Hui-Na WangHui-Na Wang3Yi Hu*Yi Hu1*Hai-Feng Qin*Hai-Feng Qin1*
  • 1Department of Oncology, Chinese People’s Liberation Army General Hospital, Beijing, China
  • 2Department of Internal Medicine, OASIS International Hospital, Beijing, China
  • 3Department of Medicine, Acornmed Biotechnology Co., Ltd., Beijing, China

A Corrigendum on:
Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient.

By Wang S-S, Wang F, Zeng Z, Gao F, Liu H-H, Wang H-N, Hu Y and Qin H-F (2022) Front. Oncol. 12:929763. doi: 10.3389/fonc.2022.929763

In the published article, there were two errors made in the Case representation section regarding the dose of pralsetinib.

Firstly, a correction has been made to Case representation, Paragraph 1 on Page 2 of the article. The sentence “He was subsequently treated with pralsetinib (600 mg orally once daily)” has been corrected to “He was subsequently treated with pralsetinib (400 mg orally once daily)”.

Secondly, a correction has been made to Case representation, Paragraph 1 on Page 3. The sentence “Therefore, he was considered to achieve a partial response (PR) according to RECIST 1.1 criteria and continued to receive pralsetinib (600 mg orally once daily)” has been corrected to “Therefore, he was considered to achieve a partial response (PR) according to RECIST 1.1 criteria and continued to receive pralsetinib (400 mg orally once daily)”.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: RET intergenic fusion, pralsetinib, lung adenocarcinoma, novel intergenic, tyrosine kinase inhibitors

Citation: Wang S-S, Wang F, Zeng Z, Gao F, Liu H-H, Wang H-N, Hu Y and Qin H-F (2022) Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient. Front. Oncol. 12:1113289. doi: 10.3389/fonc.2022.1113289

Received: 01 December 2022; Accepted: 05 December 2022;
Published: 13 December 2022.

Edited and Reviewed by:

Xianquan Zhan, Shandong First Medical University, China

Copyright © 2022 Wang, Wang, Zeng, Gao, Liu, Wang, Hu and Qin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Hai-Feng Qin, hifo@263.net; Yi Hu, huyi301zlxb@sina.com

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.